Stocktoria
Pelthos Therapeutics Inc. PTHS
NYSE American · XASE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-02-16
Pelthos Therapeutics Inc. financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $16.8M | $0 | — | — |
| R&D expense | $1.2M | $1.2M | $2.6M | $391,730 |
| SG&A expense | $42.5M | $6.4M | — | — |
| Operating income | -$32.4M | -$7.6M | -$6.9M | -$2.3M |
| Income tax | -$7.4M | $0 | — | — |
| Net income | -$43.3M | -$8.0M | -$7.4M | -$2.5M |
| EPS (diluted) | $-23.04 | $-14.27 | $-5.78 | — |
| Operating cash flow | -$22.6M | -$5.8M | -$981,031 | -$1.6M |
| Free cash flow | -$22.7M | -$5.8M | — | — |
| Cash & equivalents | $18.0M | $513,000 | $100,000 | $100,000 |
| Inventory | $23.6M | $0 | — | — |
| Total assets | $130.4M | $1.4M | $96,391 | $55,074 |
| Total liabilities | $91.5M | $4.1M | $6.5M | $3.8M |
| Shareholders' equity | $38.9M | -$2.7M | -$6.4M | -$3.7M |
Source: SEC EDGAR filings · CIK 0001919246 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.